HEPATOCELLULAR CARCINOMA

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, and it is not a cure—patients still need ongoing tre…

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This small study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with advanced liver cancer that had stopped responding to lenvatinib alone. Only 5 people were enrolled before the trial was stopped early, so we have very lim…

This study aimed to compare two standard treatments for people with large, intermediate-stage liver cancer that cannot be surgically removed. One group received a combination of two drugs (atezolizumab and bevacizumab), while the other group received a local procedure (TACE or TA…

This study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer when standard treatments failed. The goal was to see if the drugs could shrink tumors. The study was st…

This study tested a new treatment called ET140203 T cells for people with advanced liver cancer that had not responded to other therapies. The treatment involved taking a patient's own immune cells, modifying them to target cancer, and giving them back. The study was stopped earl…

This study tested whether adding a stronger chemotherapy delivery method (HAIC-TACE) to a standard targeted drug (donafenib) could help control liver cancer that cannot be surgically removed. Only 18 people enrolled before the study was stopped early, so the results are not concl…

This study tested a drug called SD-101, given directly into the liver, along with standard immunotherapy, for people with two types of liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma). The goal was to see if the combination was safe and could shrink tum…

This study tested whether adding another drug (BMS-986253 or cabiralizumab) to the immunotherapy nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. The trial was stopped early and included only 13 participants, so results are limited. …

This study tested whether adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. It was designed for patients who had already tried other treatments. However, the study was stopped early after o…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested a new drug, HFB301001, in 31 adults with advanced cancers like sarcoma and melanoma. The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in 8 people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely control the cancer and reduce the risk of organ rejection after transplant. The study was t…

This study tested a new method to improve liver biopsies for people with suspected liver cancer. It combined a GPS-like tracking system with a special dye (ICG) that makes cancer cells glow. The goal was to see if this combination could help doctors take better tissue samples. Se…

This study looked at whether tiny bits of genetic material (extracellular RNA) found in the blood can help doctors diagnose liver cancer or other liver diseases. Researchers planned to enroll about 1,865 people with liver cancer, bile duct cancer, cirrhosis, or chronic liver dise…

This study looked at whether two tiny molecules, called microRNAs, found in the blood could help diagnose liver cancer. Researchers compared levels in 10 liver cancer patients and healthy people. The goal was to see if a simple blood test could replace the need for a liver biopsy…

This study tested a special type of scan (SPECT/CT) that uses a safe radioactive tracer to measure how well the liver is working in people with liver cancer. The goal was to see if this scan can track changes in liver function during radiation or surgery. 41 adults with liver can…

This study aimed to see if certain immune cells in the blood could help predict which patients with advanced liver cancer would respond to a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after treatment in…

This pilot study tested a software called BioTraceIO 360, designed to help doctors plan and monitor liver tumor ablation (a procedure that destroys tumors with heat). The study aimed to enroll 30 people with liver cancer, but was terminated early with only 4 participants. The goa…

This study aimed to create a registry of tissue and blood samples from 1,000 people undergoing surgery or biopsy for liver or bile duct tumors. The samples were stored for future research to better understand these cancers and develop new treatments. The study was terminated earl…